About us

Pharma Press

PharmaPress.co.uk is an online news and information platform for the pharmaceutical, biopharma, and biotech industries.

It spans the full life cycle of a drug, from drug discovery and preclinical research, drug development and manufacturing, clinical trials, commercialisation, market access to patient care.

It serves as a central hub for all industry stakeholders – from scientists to pharmaceutical manufacturers to HCPs, informing and educating on the latest news and developments that impact global healthcare.

For more information, visit www.pharmapress.co.uk/latest-news/

 

Drug Discovery & Development (DDD)

Drug Discovery & Development (DDD) is dedicated to advancing scientific innovations into active medical solutions.

Its aim is to accelerate breakthroughs in medicine, addressing human disease and improving global health outcomes.

In the age of AI, DDD helps bridge the gap between early-stage scientific discoveries and bio/pharma drug development.

As part of the Pharma Press portfolio, DDD welcomes readers, partners and contributors to join its innovative and vibrant community.

Please email the team for more information about DDD, Drug Discovery & Development, the digital and printed journal.

For more information, visit www.pharmapress.co.uk/latest-news/

    Subscribe to the DDD newsletter

    Your Details


      * Required

    LATEST NEWS

    Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

    Funding & Finance
    Eli Lilly and Company and Centessa Pharmaceuticals, a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other...

    $149 a month new oral GLP-1 pill for weight loss (Foundayo (orforglipron)) now available in the US

    Drug Discovery & Development
    Eli Lilly and Company has announced that Foundayo™ (orforglipron) is now available to adults with obesity or overweight with weight-related medical problems following the US Food...

    European Commission approves Kygevvi (doxecitine and doxribtimine) as first and only treatment for thymidine kinase 2 deficiency

    Drug Discovery & Development
    UCB, a global biopharmaceutical company, has announced that the European Commission (EC) has granted marketing authorisation under exceptional circumstances for Kygevvi (doxecitine and doxribtimine)...

    Romaco Group appoints Nicola Magriotis as Chief Sales Officer

    Pharma in Healthcare
    The advisory board of Romaco Holding GmbH has appointed Nicola Magriotis as Chief Sales Officer (CSO) of the Romaco Group. By creating this new managerial...

    New report finds FDA costs soaring and drug rejections rising

    Pharma in Healthcare
    The Taxpayers Protection Alliance released a report, called Blocking Breakthroughs: Delays and Denials at the FDA, that highlights the many issues with the Food and Drug...

    Eisai and Nuvation Bio announce marketing authorisation application for taletrectinib for the treatment of advanced ROS1-positive non-small cell lung cancer validated by the European...

    Drug Discovery & Development
    Eisai Co, a human-centred global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas, and Nuvation Bio, a global oncology company...

    Ellison purchase swells triangle’s lab space

    Funding & Finance
    Oxfordshire, a key part of UK life sciences’ Golden Triangle region, had an annual take-up of lab space last year amounting to 620,200 sq...

    Inaugural International Brain Health Conference 2026 to focus on early intervention before dementia

    Events and Conferences
    International Brain Health Conference 2026 18–19 May 2026 Sheraton Grand Hotel, Edinburgh, UK  An international conference bringing together global leaders in neuroscience, clinical research, public health, and...